Birkeland, E., Busch, C., Berge, E. O., Geisler, J., Jönsson, G., Lillehaug, J. R., . . . Lønning, P. E. (2013). Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Springer Netherlands.

Birkeland, Einar, Christian Busch, Elisabet Ognedal Berge, Jürgen Geisler, Göran Jönsson, Johan Richard Lillehaug, Stian Knappskog, and Per Eystein Lønning. Low BRAF and NRAS Expression Levels Are Associated With Clinical Benefit From DTIC Therapy and Prognosis in Metastatic Melanoma. Springer Netherlands, 2013.

Birkeland, Einar, et al. Low BRAF and NRAS Expression Levels Are Associated With Clinical Benefit From DTIC Therapy and Prognosis in Metastatic Melanoma. Springer Netherlands, 2013.